Modality
ADC
MOA
PI3Ki
Target
PI3Kα
Pathway
NF-κB
GA
Development Pipeline
Preclinical
Aug 2021
→ Oct 2031
PreclinicalCurrent
NCT08778664
1,371 pts·GA
2023-10→2030-06·Active
NCT03657081
2,134 pts·GA
2021-08→2031-10·Recruiting
3,505 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-11-214mo agoEnrollment Complete· GA
2030-06-244.2y awayInterim· GA
2031-10-225.6y awayInterim· GA
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
Preclinical
Recruit…
Preclinical
Active
Catalysts
Enrollment Complete
2025-11-21 · 4mo ago
GA
Interim
2030-06-24 · 4.2y away
GA
Interim
2031-10-22 · 5.6y away
GA
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08778664 | Preclinical | GA | Active | 1371 | EASI-75 |
| NCT03657081 | Preclinical | GA | Recruiting | 2134 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxaderotide | Johnson & Johnson | NDA/BLA | PI3Kα | |
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| Rimamavacamten | Merck & Co | Phase 1 | PI3Kα | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| REG-3155 | Regeneron | Phase 1/2 | MDM2 | |
| GMA-1468 | Genmab | NDA/BLA | PI3Kα |